S-1/A: Plus Therapeutics Secures Up to $50 Million Equity Line with Lincoln Park Capital, Signaling Significant Share Dilution

Plus Therapeutics, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the company to sell up to $50 million of its common stock over 36 months, a move expected to cause substantial dilution to existing shareholders.

Summary

• Plus Therapeutics, Inc. (PSTV) has established an equity financing facility with Lincoln Park Capital Fund, LLC, enabling the company to sell up to $50 million of its common stock over a 36-month period.
• The agreement, dated June 17, 2025, provides an initial $25 million in available gross proceeds, with an automatic increase of an additional $25 million upon full utilization of the initial amount.
• The company maintains sole discretion over the timing and amount of share sales to Lincoln Park, with purchase prices based on prevailing market prices, typically at a discount (e.g., 97% of the lower of the lowest sale price on the purchase date or the average of the three lowest closing prices in the prior 10 days for regular purchases).
• Plus Therapeutics is obligated to pay Lincoln Park a $500,000 Initial Commitment Fee by August 8, 2025, and an Additional Commitment Fee of $500,000 upon receiving the initial $25 million in gross proceeds; these fees can be settled in cash or shares.
• Proceeds from the company's direct sales to Lincoln Park will be allocated for working capital, general corporate purposes, and a 'Make-Whole Repayment' of approximately $17.3 million to certain warrant holders from a March 2025 private placement.
• The filing registers up to 17,000,000 shares for resale by Lincoln Park, which, if fully issued, would represent approximately 25% of the company's 50,998,468 outstanding shares as of June 17, 2025.
• The company's common stock closed at $0.31 per share on June 16, 2025, and selling the 17,000,000 registered shares at this price would yield approximately $5.3 million in gross proceeds, leaving $44.7 million still available under the Purchase Agreement.
• As of March 31, 2025, the company reported a negative net tangible book value of approximately $(19.3) million, or $(1.44) per share, which would adjust to $(0.57) per share after the assumed sale of 17,000,000 shares at $0.31, resulting in an immediate dilution of $(0.88) per share to new investors.

Sentiment

Score: 3

Explanation: The filing details a necessary capital raise through a highly dilutive equity line, indicating ongoing financial challenges and a negative net tangible book value. While securing funding is positive for liquidity, the terms and the underlying need suggest a precarious financial position and significant shareholder value erosion.

Positives

• Secures a potential source of up to $50 million in capital over 36 months, providing crucial financial flexibility for working capital and general corporate purposes.
• The company retains control over the timing and amount of share sales to Lincoln Park, allowing for strategic capital deployment.
• The agreement includes a prohibition on Lincoln Park engaging in any direct or indirect short-selling or hedging of the company's common stock, which could help mitigate downward pressure on the stock price.
• The company has the unconditional right to terminate the Purchase Agreement at any time without fee, penalty, or cost, offering flexibility in its financing strategy.
• Proceeds will be used to address a 'Make-Whole Repayment' obligation of approximately $17.3 million, resolving a prior financing commitment and potentially simplifying the capital structure.

Negatives

• The financing mechanism is highly dilutive to existing stockholders, with up to 17,000,000 shares being registered for resale, representing approximately 25% of current outstanding shares.
• The actual amount of capital raised is dependent on the fluctuating market price of the common stock; a lower stock price necessitates the issuance of more shares for the same capital, exacerbating dilution.
• The company's net tangible book value is negative, and the offering will further dilute it from $(1.44) to $(0.57) per share, indicating significant financial challenges.
• The company will incur commitment fees totaling $1 million to Lincoln Park for the financing facility.
• There is a risk that the company may not be able to access the full $50 million available under the Purchase Agreement, especially if the stock price falls below the $0.10 floor price or if the Nasdaq Exchange Cap (19.99% of outstanding shares) is reached without stockholder approval.
• The need for this financing, coupled with the auditor's 'going concern' explanatory paragraph, highlights ongoing capital requirements and potential financial distress.

Risks

• The sale or issuance of common stock to Lincoln Park may cause substantial dilution to other stockholders.
• The sale of shares by Lincoln Park, or the anticipation of such sales, could cause the company's common stock price to fall.
• The company may not have access to the full $50 million available under the Purchase Agreement, which could materially adversely affect its business if other financing sources are unavailable.
• Even with the Lincoln Park agreement, the company may still require additional capital to finance future production plans and working capital, potentially through further dilutive equity or debt issuances.
• Management has broad discretion over the use of proceeds, and there is no guarantee that these funds will be invested successfully or yield a favorable return.
• The company needs stockholder approval to issue shares exceeding 19.99% of outstanding shares (Exchange Cap) unless the average sale price meets a certain threshold ($0.3576), or it risks breaching Nasdaq rules.
• Lincoln Park is not required to purchase shares if it would result in their beneficial ownership exceeding 4.99% of outstanding common stock, potentially limiting the company's access to funds.
• The company's independent registered public accounting firm's report contains an explanatory paragraph regarding the company's ability to continue as a going concern, indicating significant financial uncertainty.
• The offering may affect the marketability of the company's securities.
• Certain existing anti-takeover provisions in the company's charter and bylaws, and Delaware law, could delay or prevent a change in control, potentially affecting shareholder value.

Future Outlook

Plus Therapeutics plans to re-introduce its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to the U.S. market starting in the second half of 2025, following completion of necessary certifications, state licensure, payor coverages, reimbursement codes, and securing financing. The company anticipates needing additional capital beyond the Lincoln Park agreement to fund future production plans and working capital needs.

Management Comments

• Our management has broad discretion as to the use of the net proceeds from our sale of shares of common stock to Lincoln Park, and we could use them for purposes other than those currently contemplated.

Industry Context

This S-1/A filing highlights a common financing strategy for clinical-stage biotechnology or pharmaceutical companies like Plus Therapeutics, which typically have significant research and development expenses and limited or no product revenue. Equity line facilities, such as the one with Lincoln Park Capital, provide a flexible, 'at-the-market' funding source to support ongoing operations, clinical trials, and strategic initiatives without the immediate upfront dilution of a large fixed-price offering. However, they often come with substantial potential for future dilution as shares are sold into the market over time, especially for companies with low stock prices. The company's focus on targeted radiotherapeutics for CNS cancers and a diagnostic platform (CNSide) places it in a high-risk, high-reward segment of the biotech industry, where sustained capital is crucial for advancing drug candidates through lengthy and expensive clinical development.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The equity line financing structure is a common tool for small-cap biotech firms, and the specific terms (e.g., 97% of market price, $0.10 floor, 19.99% exchange cap) are typical for such arrangements, reflecting the company's current market valuation and risk profile.
• The negative net tangible book value and the 'going concern' warning are indicators that the company is operating below typical financial health standards for a mature, revenue-generating pharmaceutical company, which is common for development-stage biotechs.

Corporate Governance

Related Party Transactions

• Company Insiders participated in the May 2024 PIPE Financing at an offering price of $2.04 per Private Placement Share and accompanying Series A Common Stock Warrant and Series B Common Stock Warrant, which was slightly different from the combined purchase price of $2.022 for other initial subscribers and $2.158 for additional subscribers.

Stakeholder Impact

• **Shareholders**: Will experience substantial dilution due to the issuance of up to 17,000,000 shares (or potentially more, depending on stock price) under the Lincoln Park agreement, which could lead to a decline in share price and reduced economic and voting interests.
• **Warrant Holders (March 4, 2025)**: Certain holders will receive a 'Make-Whole Repayment' of approximately $17.3 million, funded by the proceeds from the Lincoln Park agreement, in exchange for returning previously issued shares and pre-funded warrants, providing a resolution to a prior financing commitment.
• **Creditors**: The capital raised will be used for working capital and to address the Make-Whole Repayment, which could improve the company's short-term liquidity and ability to meet obligations, but the ongoing need for capital suggests continued financial pressure.
• **Employees**: Continued operations and development of product candidates, supported by this financing, could provide stability, but the 'going concern' warning indicates underlying risks to job security.

Next Steps

• Company to continue drawing funds from Lincoln Park Capital under the Purchase Agreement over the next 36 months, at its sole discretion.
• Payment of the Initial Commitment Fee ($500,000) to Lincoln Park by August 8, 2025.
• Payment of the Additional Commitment Fee ($500,000) to Lincoln Park upon receipt of the initial $25 million in gross proceeds.
• Re-introduction of the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to the U.S. market in the second half of 2025, pending certifications, licensure, and payor coverages.
• Potential need for further capital raises beyond the Lincoln Park agreement to finance future production plans and working capital.
• Potential seeking of stockholder approval to issue shares in excess of the Nasdaq Exchange Cap (19.99%) if the average sale price to Lincoln Park does not meet the Base Price of $0.3576.

Key Dates

Recommendation

Keywords

Plus Therapeutics, PSTV, Equity Line, Lincoln Park Capital, Dilution, Capital Raise, Biotechnology, Radiotherapeutics, CNS Cancers, Glioblastoma, Leptomeningeal Metastases, Pediatric Brain Cancers, CNSide Platform, Pharmaceutical, Financing, Stock Offering, Nasdaq Capital Market, SEC Filing, S-1/A